Spots Global Cancer Trial Database for An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Official Title: A Phase 1b/2a Open-Label Study to Evaluate the Safety and Activity of Once Daily Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer
Study ID: NCT00826878
Conditions
Interventions
Study Description
Brief Summary: This is a standard Phase 1b and 2a, multi-center, study design that will examine the safety, tolerability, and maximum tolerated dose of tivozanib (AV-951) with this dosing schedule, as well as overall response rate of tivozanib (AV-951) administration in NSCLC.
Detailed Description: The Phase 2a portion of the study was not conducted
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Georgetown University, Washington, District of Columbia, United States
Kansas University Medical Center, Kansas City, Kansas, United States
Memorial Sloan-Kettering, New York, New York, United States
Contact Details
Name: Jaroslaw Jac, M.D.
Affiliation: AVEO Pharmaceuticals, Inc.
Role: STUDY_DIRECTOR
Name: Jimmy Hwang, MD
Affiliation: Georgetown University
Role: PRINCIPAL_INVESTIGATOR
Name: Chao Huang, MD
Affiliation: University of Kansas
Role: PRINCIPAL_INVESTIGATOR
Name: Naiyer Rizvi, MD
Affiliation: Memorial Sloan Kettering Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
